Methylprednisolone

Chemical formula: C₂₂H₃₀O₅  Molecular mass: 374.471 g/mol  PubChem compound: 6741

Therapeutic indications

Methylprednisolone is indicated for:

Primary adrenocortical insufficiency

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Primary adrenocortical insufficiency

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Secondary adrenocortical insufficiency

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Secondary hypocortisolism

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Congenital adrenal hyperplasia

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Congenital adrenal hyperplasia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Juvenile chronic arthritis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Chronic arthritis of juvenile onset

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Ankylosing spondylitis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Ankylosing spondylitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Systemic lupus erythematosus

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Systemic lupus erythematosus

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Dermatomyositis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Dermatomyositis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Polymyositis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Polymyositis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Carditis due to rheumatic fever

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Carditis due to rheumatic fever

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Giant cell arteritis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Temporal arteritis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Polymyalgia rheumatica

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Polymyalgia rheumatica

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Pemphigus vulgaris

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Pemphigus vulgaris

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Seasonal allergic rhinitis

Population group: only adults (18 years old or older)

Spasmodic rhinorrhea

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Perennial allergic rhinitis

Population group: only adults (18 years old or older)

Nonseasonal allergic rhinitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Hypersensitivity reaction

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Hypersensitivity reaction

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Serum sickness caused by drug

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Serum sickness caused by drug

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Allergic contact dermatitis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Allergic contact dermatitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bronchial asthma

Population group: only adults (18 years old or older)

Airway hyperreactivity

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Anterior uveitis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Anterior uveitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Posterior uveitis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Posterior uveitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Iritis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Iritis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Iridocyclitis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Iridocyclitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Optic neuritis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Optic neuritis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Pulmonary sarcoidosis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Pulmonary sarcoidosis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Disseminated tuberculosis

Population group: only adults (18 years old or older)

Fulminating or disseminated tuberculosis (with appropriate anti-tuberculous chemotherapy).

The use of corticosteroids in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen. If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Pulmonary aspiration of gastric contents

Population group: only adults (18 years old or older)

Aspiration of vomitus

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Idiopathic thrombocytopenic purpura

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Chronic idiopathic thrombocytopenic purpura

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Autoimmune hemolytic anemia

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Autoimmune hemolytic anemia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute lymphoid leukemia

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Acute lymphoid leukemia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Malignant lymphoma

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Malignant lymphoma

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Ulcerative colitis

Population group: only adults (18 years old or older)

Colitis gravis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Crohn's disease

Population group: only adults (18 years old or older)

Crohn's disease

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Tuberculous meningitis

Population group: only adults (18 years old or older)

T.B. meningitis (with appropriate antituberculous chemotherapy).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Transplantation

Population group: only adults (18 years old or older)

Transplantation

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Rheumatoid arthritis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Rheumatoid arthritis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Stevens-Johnson syndrome

Population group: only adults (18 years old or older)

Stevens-Johnson syndrome

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Stevens-Johnson syndrome

Population group: only minors (0 - 18 years old)

Stevens-Johnson syndrome

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Erythema multiforme

Population group: only adults (18 years old or older)

Erythema multiforme

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Erythema multiforme

Population group: only minors (0 - 18 years old)

Erythema multiforme

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bronchial asthma

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Airway hyperreactivity

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Seasonal allergic rhinitis

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Spasmodic rhinorrhea

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Perennial allergic rhinitis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Nonseasonal allergic rhinitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Angioneurotic oedema

Population group: only minors (0 - 18 years old)

Angioedema

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Angioneurotic oedema

Population group: only adults (18 years old or older)

Angioedema

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Anaphylaxis

Population group: only minors (0 - 18 years old)

Anaphylaxis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Anaphylaxis

Population group: only adults (18 years old or older)

Anaphylaxis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Ulcerative colitis

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Colitis gravis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Crohn's disease

Population group: only infants (40 days - 1 year old) , adolescents (12 years - 18 years old)

Crohn's disease

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Pulmonary aspiration of gastric contents

Population group: only minors (0 - 18 years old)

Aspiration of vomitus

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Disseminated tuberculosis

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Fulminating or disseminated tuberculosis (with appropriate anti-tuberculous chemotherapy).

The use of corticosteroids in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen. If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Cerebral oedema secondary to cerebral tumour

Population group: only adults (18 years old or older)

Cerebral edema and additionally Neoplasm of brain

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Cerebral oedema secondary to cerebral tumour

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Cerebral edema and additionally Neoplasm of brain

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute exacerbations of multiple sclerosis

Population group: only adults (18 years old or older)

Acute exacerbations of multiple sclerosis superimposed on a relapsing-remitting background.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute exacerbations of multiple sclerosis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Acute exacerbations of multiple sclerosis superimposed on a relapsing-remitting background.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Tuberculous meningitis

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old)

T.B. meningitis (with appropriate antituberculous chemotherapy).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Transplantation

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Transplantation

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Seborrheic dermatitis

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Seborrheic dermatitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Discoid eczema

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Nummular eczema

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Methylprednisolone is contraindicated in the following cases:

Live, attenuated vaccines

at least one of
Cholera, live attenuated
Influenza, live attenuated
Measles, combinations with mumps and rubella, live attenuated
Measles, combinations with mumps, live attenuated
Measles, combinations with mumps, rubella and varicella, live attenuated
Measles, combinations with rubella, live attenuated
Measles, live attenuated
Mumps, live attenuated
Poliomyelitis oral, monovalent live attenuated
Poliomyelitis oral, trivalent, live attenuated
Rota virus, live attenuated
Rubella, combinations with mumps, live attenuated
Rubella, live attenuated
Tuberculosis, live attenuated
Typhoid, oral, live attenuated
Varicella, live attenuated
Yellow fever, live attenuated
Zoster, live attenuated

Systemic infection

Systemic infection

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: SOLU-MEDRONE Powder for injection
Structured Product Labeling (SPL) 2019: MEDROL Tablet
Summary of Product Characteristics (SPC) 2019: MEDRONE Tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈